Avacta (AVCT:LN) develops next-generation biologics using its proprietary Affimer® platform technology. This technology is based on a naturally occurring human protein, engineered to behave like an antibody, but smaller, simpler, more robust, easy to format, cheaper and quicker to produce, highly specific to the target and non-immunogenic. In February 2019, Moderna exercised option on taking Affimer candidate(s) into clinical development.
-Lead assets are PD-L1/LAG-3 single molecule bispecific inhibitor and a PD-L1 tumour microenvironment targeted innate immune activators (I-DASH inhibitors, STING agonists)
-First-in-man clinical data expected in 2020.
-Partnerships with Moderna and OncoSec (Gene delivery), Memorial Sloan Kettering (CAR-T), Iksuda and Tufts University Medical School (Drug conjugates)
-Affimer reagents business for diagnostics and research
Near term newsflow:
-Candidate selection for anti-PD-L1/LAG-3 bispecific Affimer clinical proprietary development – (June 2019)
-Remains on track to submit an IND/CTA application by the end of 2020
-Completion of IND enabling studies for anti-PD-L1/LAG-3 bispecific - 2020
-Affimer therapeutics and reagents/diagnostics licensing
Healthcare/Medical Devices & Instruments
Unit 20, Ash Way
Thorp Arch Estate
Wetherby, York LS23 7FA
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by